A series of rulings by the Supreme Court has restricted access to the drug Mifepristone, a medication typically used with misoprostol to bring about a medical abortion and to manage early miscarriage. The drug remains on the market, and any changes to the drug’s availability have been temporarily halted. Now, the Supreme Court has agreed to take up a case clarifying what changes are actually going to be made. The case would mark the first major abortion decision since the high court overturned Roe v. Wade last year. It would also have broader implications for the authority of the FDA, potentially challenging the ability of other agencies to protect health and safety. This article from Northeastern Global News gives insight into this historic case, featuring input from Northeastern’s Wendy Parmet (Law, Public Policy and Urban Affairs) and Daniel Urman (Law).
Read the full article here!
Photo by Soumyabrata Roy/NurPhoto via AP
